.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,569,347

« Back to Dashboard

Details for Patent: 8,569,347

Title:Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s): Lee; Francis Y. F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:May 20, 2004
Application Number:10/850,072
Claims:1. A method for treating lung cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula, ##STR00020## or a pharmaceutically-acceptable hydrate, solvate, or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone.

2. The method of claim 1 wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.

3. The method of claim 1 wherein the antibody C225 is administered following the administration of Compound (1).

4. The method according to claim 1, wherein the antibody C225 is administered before the administration of Compound (1).

5. The method according to claim 1, wherein the antibody C225 is administered substantially simultaneously with the administration of Compound (1).

6. The method according to claim 1, wherein the antibody C225 and the Compound (1) are both administered parenterally.

7. The method according to claim 1, wherein the cancer is non-small cell lung cancer.

8. A method for treating pancreatic cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula, ##STR00021## and/or a pharmaceutically-acceptable hydrate, solvate, and/or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone.

9. The method of claim 8, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.

10. The method of claim 7, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc